

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION



Name Tagliabue Elda
Address P.zza De Gasperi, 3 20091 Bresso (Milano)
Telephone (39)02-23903013
Fax (39)02-23902692
E-mail elda.tagliabue@istitutotumori.mi.it
Nationality Italian
Date of birth 23th September 1955

WORK EXPERIENCE

- Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
- Main activities and responsibilities
 - Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
 - Main activities and responsibilities
 - Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
 - Main activities and responsibilities
 - Dates (from – to)
• Name and address of employer
• Type of business or sector
• Occupation or position held
 - Main activities and responsibilities

| | |
|--|--|
| <ul style="list-style-type: none"> • Dates (from – to) • Name and address of employer <ul style="list-style-type: none"> • Type of business or sector • Occupation or position held • Main activities and responsibilities | <p>1983-1985 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Experimental Oncology Research Associate, Division of Experimental Oncology A Designing and executing experiments in the field of tumor immunology, production of monoclonal antibody directed against tumor associated antigens</p> |
|--|--|

EDUCATION AND TRAINING

| | |
|--|---|
| <ul style="list-style-type: none"> • Dates (from – to) • Name and type of organisation providing education and training • Principal subjects/occupational skills covered • Title of qualification awarded • Level in national classification (if appropriate) | <p>1974-1978 University of Milan Degree in Biological Science</p> |
| <ul style="list-style-type: none"> • Dates (from – to) • Name and type of organisation providing education and training • Principal subjects/occupational skills covered • Title of qualification awarded • Level in national classification (if appropriate) | <p>1969-1974 High School, Milan Classical Studies Baccalaureate</p> |

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH

GOOD
GOOD
GOOD

SOCIAL SKILLS

AND COMPETENCES

Living and working with other people, in multicultural environments, in positions where communication is important and situations where teamwork is essential (for example culture and sports), etc.

Editorial Boards

- Member of the Editorial Board of Chinese Journal of Clinicians
- Member of the Editorial Board of International Journal of Biological Markers
- Member of the Editorial Board of Journal of Solid Tumors
- Member of the Editorial Board of PLoS One
- Barts and the London Charity
- Irish Health Research Board

Peer-Review Research Evaluation of National (AIRC and MIUR)) and international programs (Dutch Cancer Society, Institut National du Cancer and Irish Health Research Board).

Ad Hoc reviewer for: Annals of Oncology, BC Research, BC Research and Treatment, British Journal of Cancer, Cancer Detection and Prevention, Cancer Research, European Journal of Cancer, International Journal of Cancer, Journal of Cellular Physiology, The Oncologist, Oncogene and Tumor Biology.

Scientific associations

National

- Italian Society of Cancerology (SIC)

International

- American Association for Cancer Research (AACR)
- International Cancer Microenvironment Society (ICMS)
- European Association for Cancer Research (EACR)
- European Academy of Tumor Immunology (EATI)

In 2013, Dr. Tagliabue became a Board Member of the Italian Society of Cancerology (SIC). Sponsored by Italian Ministry of Health, European Community and AIRC (Italian Association for Cancer Research).

Dr Tagliabue counts numerous invitations to national and international conferences. She has been responsible for several projects funded by AIRC; Italy-USA Program on Cancer Research; Cariplo Foundation, MIUR and Alliance Against Cancer.

Throughout her career, Dr. Elda Tagliabue has been involved in both clinical and pre-clinical research addressing the role of HER2 oncprotein and receptors for adhesion molecules in breast cancer tumorigenesis, progression and response to therapy. This work has produced more than 250 publications in peer-reviewed journals —data according to Scopus: total number of citations:12.193; H index: 59— and 21 co-authored books. Dr. Tagliabue furthered her scientific experience through collaborations and additional training periods in internationally recognized laboratories such as the Metastasis Laboratory of Liege University and The Weizmann Institute of Science of Rehovot, Israel, where she focused on the purification of adhesion molecule receptors and on the function of growth factor receptors, respectively. By addressing the role of HER2 oncprotein in breast cancer tumorigenesis and progression, Dr. Tagliabue showed for the first time that HER2 overexpression plays a role in post-surgery stimulation of growth of breast carcinoma cells (*Lancet* 2003), shedding light on the mechanism involved in the early relapse which characterizes these patients. In 2004, she contributed to the demonstration that trastuzumab can mediate ADCC in HER2-positive breast carcinoma patients (*Clin Cancer Res* 2004), leading the way toward in-depth analysis of host immune system responsibility for trastuzumab efficacy and currently followed by several groups involved in optimization of HER2-targeted therapies. In the last years, Dr. Tagliabue's expertise in translational research has contributed greatly in accomplishing three different observational studies on the role of HER2 in tumor progression and trastuzumab activity in the Italian clinical practice, all supported by Roche and successfully published in the relevant journals. Very recently, her team identified a new molecular classifier predictive of adjuvant trastuzumab benefit (*Oncotarget* 2015) and discovered a mechanism through which chemotherapy could maximize the antibody effect (*Oncotarget* 2016). In 2018, Dr. Tagliabue demonstrated that HER2 signaling directly influences the recruitment of immune cells regulating the tumor immune microenvironment and trastuzumab efficacy (*Oncolmmunology* 2019).

Concerning the study of tumor/stroma interaction, Dr. Tagliabue strongly contributed to shed light on the mechanism by which the monomeric laminin receptor plays a major role in tumor aggressiveness and metastasis (*Cancer Res* 2002). In collaboration with the Department of Genetics at the Norwegian Radium Hospital in Oslo, she demonstrated that breast carcinomas can be sub grouped according to extracellular matrix features (*J of Pathol* 2008), paving the way for analysis of extracellular matrix significance in breast cancer progression. Consequently, Dr. Tagliabue's group found that differential expression of ECM genes delineates a robust cluster that identifies breast carcinomas with EMT features but with accelerated metastatic potential only in the undifferentiated phenotype (*PLoS One* 2013) and so opening a discussion on the clinical relevance of stromal signatures. In 2016, she contributed to the demonstration that mesenchymal transition of high-grade breast carcinomas depends on extracellular matrix control of myeloid suppressor cell activity (*Cell Rep.* 2016).

In 2018 she awarded a Grant AIRC aimed at understanding the contribution of gut microbiota in trastuzumab activity to improve drug responsiveness. About this, Dr Tagliabue provided evidence of gut microbiota involvement in trastuzumab efficacy representing the foundation for new therapeutic strategies aimed at manipulating commensal bacteria to improve response in trastuzumab-resistant patients (*Cancer Res.*, 2021).

Mentoring activity of Dr. Tagliabue led to numerous Bachelor and Master of Science graduates Concerning Doctors in Philosophy, she examined numerous UK and non-UK PhD students and successfully supervised 9 UK PhD students. More than 10 monoclonal antibodies produced by Dr. Tagliabue's team are now commercially available and abroad used for research.

**ORGANISATIONAL SKILLS
AND COMPETENCES**

Coordination and administration of people, projects and budgets; at work, in voluntary work (for example culture and sports) and at home, etc.

Good communication skills gained through experience as responsible of a research team. Currently responsible for a team of 20 researchers involved in the translational research of breast carcinoma

**TECHNICAL SKILLS
AND COMPETENCES**

With computers, specific kinds of equipment, machinery, etc.

Good command of cell culture, transfection, Western blot, immunoprecipitation, protein and nucleic acid purification, cytofluorimetric analysis, immunohistochemistry, qPCR, somatic fusion and selection of monoclonal antibodies

Design of laboratory experiments, discussion and interpretation of obtained results, planning of new research projects, writing of scientific papers and grants. Good command of Microsoft Office™ tools

La sottoscritta è a conoscenza che, ai sensi dell'art.76 DPR 28/12/2000 n.445, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto, ai sensi della vigente normativa nazionale ed europea in tema di protezione dei dati personali, in particolare del Regolamento UE 2016/679, autorizza la Fondazione IRCCS Istituto Nazionale dei Tumori di Milano al trattamento dei dati personali per l'espletamento delle attività necessarie alla realizzazione di attività formative, accreditate ECM e non, e inserite nel piano di formazione dello stesso Istituto".

Milan, February 3rd, 2023

Elda Tagliabue

Publications of the last five years

- Bernardo G, Le Noci V, Ottaviano E, De Cecco L, Camisaschi C, Guglielmetti S, Di Modica M, Gargari G, Bianchi F, Indino S, Sartori P, Borghi E, Sommariva M, **Tagliabue E**, Triulzi T, Sfondrini L. Reduction of *Staphylococcus epidermidis* in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness. *Cancer Lett.* 2023 Feb 28;555:216041.
- Perrone M, Chiodoni C, Lecchi M, Botti L, Bassani B, Piva A, Jachetti E, Milani M, Lecis D, **Tagliabue E**, Verderio P, Sangaletti S, Colombo MP. ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation. *Cancer Res.* 2023 Jan 4;83(1):117-129
- Cairo A, Iorio MV, Spena S, **Tagliabue E**, Peyvandi F. Worldwide SARS-CoV-2 haplotype distribution in early pandemic. *PLoS One.* 2022 Feb 16;17(2):e0263705.
- De Santis F, Romero-Cordoba SL, Castagnoli L, Volpari T, Faraci S, Fucà G, **Tagliabue E**, De Braud F, Pupa SM, Di Nicola M. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer. *Cell Oncol (Dordr)* 2022;45(2):257-274.
- Di Modica M, Arlotta V, Sfondrini L, **Tagliabue E**, Triulzi T. The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine. *Front Oncol.* 2022 Jul 13;12:947188.
- Fogazzi V, Kapahnke M, Cataldo A, Plantamura I, **Tagliabue E**, Di Cosimo S, Cosentino G, Iorio MV. The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective. *Cancers (Basel).* 2022 Oct 29;14(21):5326
- Le Noci V, Bernardo G, Manenti G, Infante G, Khaleghi Hashemian D, Minoli L, Canesi S, Bianchi F, Triulzi T, Arioli S, De Cecco L, Guglielmetti S, Ambrogi F, Recordati C, Gagliano N, **Tagliabue E**, Sommariva M, Sfondrini L. Live or Heat-Killed Lactobacillus rhamnosus Aerosolization Decreases Adenomatous Lung Cancer Development in a Mouse Carcinogen-Induced Tumor Model. *Int J Mol Sci.* 2022 Oct 22;23(21):12748.
- Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, **Tagliabue E**, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G. Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. *J Natl Cancer Inst.* 2022 Jul 5: djac126.
- Perrone M, Chiodoni C, Lecchi M, Botti L, Bassani B, Piva A, Jachetti E, Milani M, Lecis D, **Tagliabue E**, Verderio P, Sangaletti S, Colombo MP. ATF3 reprograms the bone marrow niche in response to early breast cancer transformation. *Cancer Res.* 2022 Nov 1: CAN-22-0651.
- Pizzamiglio S, Cosentino G, Ciniselli CM, De CL, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, **Tagliabue E**, Di Cosimo S, Iorio MV. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. *Cancer Med* 2022
- Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglavov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, **Tagliabue E**. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. *Mol Oncol.* 2022 Jun;16(12):2355-2366.
- Bianchi F, Sommariva M, Le Noci V, Camelliti S, Gagliano N, Giussani M, Balsari A, **Tagliabue E**, Sfondrini L. Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity. *PLoS ONE* 16 (3):e0248789, 2021.
- Camelliti S, Le Noci V, Bianchi F, Storti C, Arnaboldi F, Cataldo A, Indino S, Jachetti E, Figini M, Colombo MP, Balsari A, Gagliano N, **Tagliabue E**, Sfondrini L, Sommariva M. Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. *Cancers (Basel)* 13 (16):4081, 2021.
- Cosentino G, Plantamura I, **Tagliabue E**, Iorio MV, Cataldo A. Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. *Cancers (Basel).* 13 (15):3691, 2021.
- Di Modica M, Gargari G, Regondi V, Bonizzi A, Arioli S, Belmonte B, De Cecco L, Fasano E, Bianchi F, Bertolotti A, Tripodo C, Villani L, Corsi F, Guglielmetti S, Balsari A, Triulzi T, **Tagliabue E**. Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer. *Cancer Res.* 81:2195-2206, 2021.
- Giussani M, Ciniselli CM, De Cecco L, Lecchi M, Dugo M, Gargiuli C, Mariancini A, Mancinelli E, Cosentino G, Veneroni S, Paolini B, Orlandi R, Gennaro M, Iorio MV, Depretto C, Ferranti C, Sozzi G, Sensi M, Colombo MP, Scaperrotta G, **Tagliabue E**, Verderio P. Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended. *Cancers (Basel)* 13 (16):4028, 2021.
- Le Noci V, Bernardo G, Bianchi F, **Tagliabue E**, Sommariva M, Sfondrini L. Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression. *Front Cell Dev Biol.* 19, 732192, 2021
- Lecchi M, Verderio P, Cappelletti V, De Santis F, Paolini B, Monica M, Sangaletti S, Pupa SM., Iorio MV, Bianchi G, Gennaro M, Fuca G, De Braud F, **Tagliabue E**, Di Nicola M. A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis. *Mol Oncol* 15:1345-1357, 2021.
- McKee AM, Kirkup BM, Madgwick M, Fowler WJ, Price CA, Dreger SA, Ansorge R, Makin KA, Caim S, Le Gall G, Paveley J, Leclaire C, Dalby M, Alcon-Giner C., Andrusaita A, Feng TY, Di Modica M, Triulzi T, **Tagliabue E**, Milling SWF, Weilbaecher KN, Rutkowski MR, Korcsmaros T, Hall LJ, Robinson SD. Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. *iScience* 24 (9):103012, 2021.
- Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, De Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart M, Daidone MG, Pruneri G, Colombo MP, **Tagliabue E**, Verderio P, Di Cosimo S.

- Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis. *Clin Cancer Res.*, 2021.
- Pizzamiglio S, Cosentino G, Ciniselli CM, De CL, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, **Tagliabue E**, Di Cosimo S, Iorio MV. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. *Cancer Med* 2021 Dec 17;10
- Rybinska I, Mangano N, **Tagliabue E**, Triulzi T. Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences. *Int J Mol Sci.* 22 (7):3775, 2021.
- Tagliabue E.** Special Issue: Micro- and Macro-Environmental Factors in Solid Cancers. *Cells* 10 (2):247, 2021.
- Agnolon V, Contato A, Meneghelli A, **Tagliabue E**, Toffoli G, Gion M, Polo F, Fabricio ASC. ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer-patients undergoing therapy with trastuzumab. *Sci Rep* 10: 3016, 2020.
- Bianchi F, Alexiadis S, Camisaschi C, Truini M, Centonze G, Milione M, Balsari A, **Tagliabue E**, Sfondrini L. TLR3 Expression Induces Apoptosis in Human Non-Small-Cell Lung Cancer. *Int J Molec Sci* 21: 1440, 2020.
- Camelliti S, Le Noci V, Bianchi F, Moscheni C, Arnaboldi F, Gagliano N, Balsari A, Garassino MC, **Tagliabue E**, Sfondrini L, Sommariva M. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. *J Exp Clin Cancer Res* 39: 236, 2020.
- Castagnoli L, De Santis F, Volpari T, Vernieri C, **Tagliabue E**, Di Nicola M, Pupa SM. Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure. *Cells* 9: E555, 2020.
- Castagnoli L., **Tagliabue E.**, Pupa S. M. Inhibition of the Wnt signalling pathway: an avenue to control breast cancer aggressiveness. *Int J Mol Sci* 21: E9069, 2020.
- Cataldo A, Romero-Cordoba S., Plantamura I., Cosentino G., Hidalgo-Miranda A., **Tagliabue E.**, Iorio M. V. MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer. *Cancers (Basel)* 12: E2261, 2020.
- Majorini, M.T.; Cancila, V.; Rigoni, A.; Botti, L.; Dugo, M.; Triulzi, T.; De Cecco, L.; Fontanella, E.; Jachetti, E.; **Tagliabue, E.**; Chiodoni, C.; Tripodo, C.; Colombo, M.P.; Lecis, D. Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype. *Cancer Res* 80: 2311-2324, 2020.
- Mocenigo M, Porchetta A, Rossetti M, Brass E, Tonini L, Puzzi L, **Tagliabue E**, Triulzi T, Marini B, Ricci F, Ippodrino R. Rapid, Cost-effective Peptide/nucleic acid-based Platform for Therapeutic Antibody Monitoring in Clinical Samples. *ACS Sens* 5; 3109-3115, 2020.
- Romero-Cordoba S, Salido-Guadarrama I, Meneses ME, Cosentino G, Iorio MV, **Tagliabue E**, Torres N, Sanchez-Tapia M, Bonilla M, Castillo I, Petlacaclco B, Tovar AR, Martinez-Carrera D. Mexican Ganoderma lucidum extracts decrease lipogenesis modulating transcriptional metabolic networks and gut microbiota in C57BL/6 mice fed with a high-cholesterol diet. *Nutrients* 13: E38, 2020.
- Rossini, A.; Giussani, M.; Ripamonti, F.; Aiello, P.; Regondi, V.; Balsari, A.; Triulzi, T.; **Tagliabue, E.** Combined targeting of EGFR and HER2 against prostate cancer stem cells. *Cancer Biol Ther* 21: 463-475, 2020.
- Rybinska, I.; Agresti, R.; Trapani, A.; **Tagliabue, E.**; Triulzi, T. Adipocytes in Breast Cancer, the Thick and the Thin. *Cells* 9: E560, 2020.
- Rybinska, I.; Sandri, M.; Bianchi, F.; Orlandi, R.; De Cecco, L.; Gasparini, P.; Campiglio, M.; Paolini, B.; Sfondrini, L.; **Tagliabue, E.**; Triulzi, T. Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment. *Cells* 9: E434, 2020.
- Sommariva, M.; Le Noci, V.; Bianchi, F.; Camelliti, S.; Balsari, A.; **Tagliabue, E.**; Sfondrini, L. The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. *Cell Mol Life Sci* 77: 2739-2749, 2020.
- Tiwari, S.; Triulzi, T.; Holton, S.; Regondi, V.; Paolini, B.; **Tagliabue, E.**; Bhargava, R. Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer. *Sci Rep* 10: 5442, 2020.
- Agresti R, Triulzi T, Sasso M, Ghirelli C, Aiello P, Rybinska I, Campiglio M, Sfondrini L, **Tagliabue E**, Bianchi F. Wound healing fluid reflects the inflammatory nature and aggressiveness of Breast Tumors. *Cells* 8: 181, 2019.
- Beltran-Anaya FO, Romero-Cordoba S, Rebollar-Vega R, Arrieta O, Bautista-Pina V, Dominguez-Reyes C, Villegas-Carlos F, Tenorio-Torres A, Alfaro-Riu L, Jimenez-Morales S, Cedro-Tanda A, Rios-Romero M, Reyes-Grajeda JP, **Tagliabue E**, Iorio MV, Hidalgo-Miranda A. Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. *Mol Oncol.* 13:909-927,2019.
- Bianchi F, Milione M, Casalini P, Centonze G, Le Noci V, Storti C, Alexiadis S, Truini M, Sozzi G, Pastorino U, Balsari A, **Tagliabue E**, Sfondrini L. Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. *Sci Rep.* 9:14288-50756,2019.
- Castagnoli L, Ladomery M, **Tagliabue E**, Pupa SM. The d16HER2 splice variant: a friend or foe of HER2-positive cancers? *Cancers (Basel)* 11,2019.
- Castagnoli L, Iorio E, Dugo M, Koschorke A, Faraci S, Canese R, Casalini P, Nanni P, Vernieri C, Di Nicola M, Morelli D, **Tagliabue E**, Pupa SM. Intra-tumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. *J Cell Physiol.* 234:1768-1779,2019.
- Castagnoli L, Cancila V, Romero-Cordoba SL, Faraci S, Talarico G, Belmonte B, Iorio MV, Volpari T, Chiodoni C, Hidalgo-Miranda A, **Tagliabue E**, Tripodo C, Sangaletti S, Di Nicola M, Pupa SM. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. *Oncogene* 38:4047-4060,2019.
- Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, De Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Pena L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, De Braud FG, Apolone G, Verderio P, **Tagliabue E**. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. *Eur J Cancer* 118:1-9,2019.
- Giussani M, Triulzi T, Sozzi G, **Tagliabue E**. Tumor extracellular matrix remodeling: new perspectives as a circulating tool in the diagnosis and prognosis of solid tumors. *Cells* 8,2019.
- Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, Vernieri C, De Braud F, Di Nicola M, **Tagliabue E**, Castagnoli L, Pupa SM. Phenethyl isothiocyanate hampers growth and progression of HER2-positive

- breast and ovarian carcinoma by targeting their stem cell compartment. *Cell Oncol.(Dordr.).* 42:815-828,2019.
- Le Noci V, Sommariva M, Bianchi F, Triulzi T, **Tagliabue E**, Balsari A, Sfondrini L. Local administration of caloric restriction mimetics to promote the immune control of Lung Metastases. *J Immunol.Res.* 2019:2015892,2019.
- Pastorino U, **Tagliabue E**. Non-Human Determinants of Lung Cancer Outcome: A Target for Inhibition of Pro-Metastatic Effect of Surgery, Triggered by Postoperative Bacterial Pneumonia. *J Thorac Oncol* 14:2039-2041,2019.
- Romero-Cordoba S, Meneghini E, Sant M, Iorio MV, Sfondrini L, Paolini B, Agresti R, **Tagliabue E**, Bianchi F. Decoding immune heterogeneity of Triple Negative Breast Cancer and its association with systemic inflammation. *Cancers (Basel)* 11,2019.
- Volpi CC, Pietrantonio F, Gloghini A, Fuca G, Giordano S, Corso S, Pruner G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, De Braud F, Di Nicola M, **Tagliabue E**, Pupa SM, Castagnoli L. The landscape of d16HER2 splice variant expression across HER2-positive cancers. *Sci.Rep.* 9:3545,2019.
- Andriani F, Landoni E, Mensah M, Facchinetto F, Miceli R, **Tagliabue E**, Giussani M, Callari M, De Cecco L, Colombo MP, Roz L, Pastorino U, Sozzi G. Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. *BMC Cancer* 18:899,2018.
- Cataldo A, Piovan C, Plantamura I, D'Ippolito E, Camelliti S, Casalini P, Giussani M, Deas O, Cairo S, Judd JG, **Tagliabue E**, Iorio MV. MIR-205 as predictive biomarker and adjuvant therapeutic tool in combination with Trastuzumab. *Oncotarget* 9:27920-27928,2018.
- De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Franceschini D, Fuca G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, **Tagliabue E**, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M. Innovative therapy, monoclonal antibodies, and beyond: highlights from the eighth annual meeting. *Cytokine Growth Factor Rev.* 44:1-10, 018.
- Dugo M, Huang X, Iorio MV, Cataldo A, **Tagliabue E**, Daidone MG, Wu J, Orlandi R. MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. *Breast* 39:46-52,2018.
- Forte L, Turdo F, Ghirelli C, Aiello P, Casalini P, Iorio MV, D'Ippolito E, Gasparini P, Agresti R, Belmonte B, Sozzi G, Sfondrini L, **Tagliabue E**, Campiglio M, Bianchi F. The PDGFRbeta/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. *BMC Cancer* 18:586,2018.
- Giussani M, Landoni E, Merlino G, Turdo F, Veneroni S, Paolini B, Cappelletti V, Miceli R, Orlandi R, Triulzi T, **Tagliabue E**. Extracellular matrix proteins as diagnostic markers of breast carcinoma. *J Cell Physiol.* 233:6280-6290,2018.
- Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, **Tagliabue E**, Sfondrini L. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: A strategy to promote immunosurveillance against lung metastases. *Cell Rep.* 24:3528-3538,2018.
- Majorini MT, Manenti G, Mano M, De Cecco L, Conti A, Pincioli P, Fontanella E, **Tagliabue E**, Chiodoni C, Colombo MP, Delia D, Lecis D. cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells. *Cell Death Differ.* 25:2147-2164,2018.
- Moriggi M, Giussani M, Torretta E, Capitanio D, Sandri M, Leone R, De Palma S, Vasso M, Vozzi G, **Tagliabue E**, Gelfi C. ECM remodelling in Breast Cancer with different grade: Contribution of 2D-DIGE Proteomics. *Proteomics* 18:e1800278,2018.
- Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini P-L, Di Cosimo S, Sfondrini L, Generali D, **Tagliabue E**. Early immune modulation by single agent trastuzumab as a marker of trastuzumab benefit. *Br.J.Cancer* 119:1487-1494,2018.
- Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, Sfondrini L, Balsari A, **Tagliabue E**. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. *Oncolmmunology* 8:e1512942,2018.